Table 2.
Factors associated with prevalent liver-related outcomes.
| Liver-related outcomes or death OR (95% CI) |
p value | |
|---|---|---|
| MRE | ||
| <3.63 kPa (referent) | Ref | |
| 3.63–5 kPa | 13.37 (2.68–66.64) | 0.0015 |
| >5 kPa | 41.61 (12.40–139.66) | <0.0001 |
| Demographic and biochemical | ||
| BMI (kg/m2) | 1.04 (0.99–1.10) | 0.1397 |
| HbA1c (%) | 1.42 (1.03–1.95) | 0.0309 |
| AST (U/l) (per 5-unit increase) | 1.20 (1.10–1.30) | <0.0001 |
| ALT (U/l) (per 5-unit increase) | 1.04 (0.98–1.10) | 0.1881 |
| Alkaline phosphatase (U/l) (per 5-unit increase) | 1.25 (1.15–1.36) | <0.0001 |
| Total bilirubin (mg/dl) | 18.23 (6.55–50.77) | <0.0001 |
| Albumin (g/dl) | 0.007 (0.001–0.046) | <0.0001 |
| HOMA-IR | 1.07 (1.03–1.12) | 0.0026 |
| Triglycerides (mg/dl) (per 5-unit increase) | 1.02 (0.99–1.04) | 0.1409 |
| HDL (mg/dl) (per 5-unit increase) | 0.78 (0.65–0.94) | 0.0083 |
| LDL (mg/dl) (per 5-unit increase) | 0.88 (0.81–0.95) | 0.0017 |
| Platelet count (109/l) (per 10-unit increase) | 0.77 (0.71–0.84) | <0.0001 |
| Clinical score | ||
| FIB-4 | 2.39 (1.77–3.22) | <0.0001 |
| NAFLD Fibrosis Score | 3.07 (2.08–4.53) | <0.0001 |
| MELD score (per 1-unit increase) | 1.63 (1.36–1.96) | <0.0001 |
| Positive MEFIB | 42.89 (13.26–138.73) | <0.0001 |
| Imaging | ||
| MRI-PDFF | 0.90 (0.80–1.02) | 0.0959 |
ALT, alanine aminotransferase; AST, aspartate aminotransferase; BMI, body mass index; FIB-4, fibrosis index based on the 4 factors; HbA1c, hemoglobin A1c; HDL, high-density lipoprotein; HOMA-IR, homeostatic model assessment method for insulin resistance (calculated as (fasting insulin (μU/ml) × fasting glucose (mmol/l)) / 22.5); INR, international normalized ratio; LDL, low-density lipoprotein; MRI-PDFF, MRI-based proton density fat fraction. Statistically significant p values are denoted in bold.